Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Leukemia & Lymphoma | May 9, 2018 | Volume: 60 | Issue: 1 | Pages: 163-171
10.1080/10428194.2018.1459609
| PMID 29741423